Metacam®

(meloxicam)

1.5 mg/mL Oral Suspension (equivalent to 0.05 mg per drop) 0.5 mg/mL Oral Suspension (equivalent to 0.02 mg per drop)

Non-steroidal anti-inflammatory drug for oral use in dogs only Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Warning: Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications. Warnings, and Precautions for detailed information.

Description: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Each milliliter of Metacam Oral Suspension contains meloxicam equivalent to 0.5 or 1.5 milligrams and sodium benzoate (1.5 milligrams) as a preservative. The chemical name for Meloxicam is 4-Hydroxy-Z-methyl-N-45-methyl-2-thiazoJVJ-2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide. The formulation is a yellowish viscous suspension with the odor of honey.

Indications: Metacam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Dosage and Administration: Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of Metacam and other treatment options before deciding to use Metacam. Use the lowest effective dose for the shortest duration consistent with individual response. Metacam Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, Metacam Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/kg). The syringe is calibrated to deliver the daily maintenance dose in pounds.

Directions for Administration (1.5 mg/mL strength): Dogs under 10 pounds (4.5 kg)

Dugs under 10 pounds (4.5 Kg) Shake well before use, then remove cap. Particular care should be given with regard to the accuracy of dosing. To prevent accidental verdosing of small dogs, administer drops on food only, never directly into the mouth. Carefully measure suspension onto food to assure that the correct dose is given before presentation of the food to the dog. The syringe provided with the meloxicam concentration of 1.5 mg/mL cannot be used to measure doses for dogs weighing less than 5 lbs (2.3 kg).

For dogs less than 5 lbs (2.3 kg), Metacam Oral Suspension can be given using the dropper bottle: one drop for each pound of body weight for the 1.5 mg/mL concentration (two drops for each kilogram of body weight), dropped directly onto the food.

For dogs between 5-10 pounds, Metacam Oral Suspension can be given by drops or by using the measuring syringe provided in the package (see dosing procedure below). The syringe fits on to the bottle and has a scale beginning at 5 lbs, designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog's weight should be rounded down to the nearest 5 pound increment. Replace and tighten cap after use.

Weight should be founded down to the freatest's pound intrometine. Replace and tigned can be down to the freatest's pound (4.5 Kg) Dogs over 10 pounds (4.5 Kg) Shake well before use then remove cap. Metacam Oral Suspension may be either mixed with food or placed directly into the mouth. Particular care should be given with regard to the accuracy of dosing. Metacam Oral Suspension can be given using the measuring syninge provided in the package (see dosing procedure below). The syringe fits on to the bottle and has a scale in pounds designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog's weight should be rounded down to the nearest 5 pound increment. Alternatively, Metacam Oral Suspension can be given using the dropper bottle: one diop for each pound of body weight for the 1.5 mg/mL concentration (two drops for each kilogram of body weight). Replace and tighten cap after use.

To fing the Concentration (two drops to each shogtain to body weight), replace and ugnet cap after use. Directions for Administration (0.5 mg/mL strength): Dogs under 10 pounds (4.5 kg) Shake well before use, then remove cap. Particular care should be given with regard to the accuracy of dosing. To prevent accidental overdosing of small dogs, administer drops on food only, never directly into the mouth. Carefully measure suspension onto food to assure that the correct dose is given before presentation of the food to the dog. The syringe provided with the meloxicam concentration of 0.5 mg/mL cannot be used to measure doses for dogs weighing less than 1 lb (0.45 kg).

For dogs less than 1 lb (0.45 kg), Metacam Oral Suspension can be given using the dropper bottle: two drops for each pound of body weight for the 0.5 mg/mL concentration (five drops for each kilogram of body weight), dropped directly onto the food.

For dogs between 1-10 pounds, Metacam Oral Suspension can be given by drops or by using the measuring syringe provided in the package (see dosing procedure below). The syringe fits on to the bottle and has a scale beginning at 1 lb, designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog's weight should be rounded down to the nearest 1 pound increment. Replace and tighten cap after use. Dogs over 10 pounds (4.5 kg)

Shake well before use then remove cap. Metacam Oral Suspension may be either mixed with food or placed directly into the mouth. Particular care should be given with regard to the accuracy of dosing. Metacam Oral Suspension can be given using the measuring syninge provided in the package (see dosing procedure below). The syringe fits on to the bottle and has a scale in pounds designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog's weight should be rounded down to the nearest 1 pound increment. Alternatively, Metacam Oral Suspension can be given using the dropper bottle: two drops for each pound of body weight for the 0.5 mg/mL concentration (five drops for each kilogram of body weight). Replace and tighten cap after use.







Shake bottle well. Push down and unscrew bottle top. Attach the dosing syringe to the bottle by gently pushing the end on to the top of the bottle.

Turn the bottle/syringe upside down. Pull the plunger out until the black line on the plunger corresponds to the dog's body weight in pounds Turn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle. weight in pounds.


Contraindications: Dogs with known hypersensitivity to meloxicam should not receive Metacam Oral Suspension. Do not use Metacam Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats

TI 2

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in c of accidental ingestion by humans. For oral use in dogs only. As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about Metacam.

The safe use of Metacam Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, oring preparator relating dogs have a client information sheet about Metacam. Precautions: The safe use of Metacam Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, oring preparator at lactating dogs has not been established in dogs with these disorders. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAID samy result in clinically significant disease in patients with underlying or pre-existing disease that have nepreince adverse reactions from normal homeostatic function. Should be avoided. If additional pain medication is needed after administration of the total daily dose of Metacam Oral Suspension, a non-NSAID or non-corticosteriol class of analisesia should be considered. The use of another NSAID to another in dogs. The use of appropriate washout times when switching from corticosteriod user form one NSAID to another in dogs. The used protein-bound drugs include cardica, anticonvulsant and behavioral medications. The influence of concomitant drugs that may be considered. The use of another MSAID to another in dogs. The used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of Metacam Oral Suspension has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomit monitored in patients requiring adjunctive therapy.



Adverse Reactions Observed During Two Field Studies

Clinical Observation	Meloxicam (n=157)	Placebo (n=149)
Vomiting	40	23
Diarrhea/Soft Stool	19	11
Bloody Stool	1	0
Inappetance	5	1
Bleeding gums after dental procedure	1	0
Lethargy/Swollen Carpus	1	0
Epiphora	1	0

In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog). **Post-Approval Experience (Rev. 2010)**: The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of frequency by body system. *Gastrointestinal:* vomiting, anorexia, diarrhea, melena, gastrointestinal ulceration *Urinary:* azotermia, elevated creatinine, renal failure *Neuroloaicul/Behaviorali:* [Etharwar, denerscinn]

Neurological/Behavioral: lethargy, depression Hepatic: elevated liver enzymes

Dermatologic: pruritus

Demotologic: pruritus Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with use of medoxicam in cats. To report suspected adverse reactions, to obtain a Material Safety Data Sheet, or for technical assistance, call 1-866-METACAM (1-866-638-2226). For a complete listing of adverse reactions for meloxicam reported to the CVM see: http://www.tda.gov/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/ucm055394.htm Information for Dog Owners: Metacam, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice. Harver, incordination, seizur, or behavioral changes. Serious adverse reactions associated with water consumption, increased urination, pale gum 3 due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death (see Adverse Reactions). Owners should be advised to discontinue Metacam and contact their veterinarian immediately if signs of incolerance are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration and wNSAID. Clinical Pharmacology: Meloxicam has nearly 100% bioavailability when administered orally with food. The terminal elimination half life after a single dose is estimated to be approximately 24 hrs (+/-30%) regardless of route of administration. There is no evidence of statistically significant gender differences in drug pharmacokinetics. Drug bioavailability, volume of distribution, and total systemic clearance remain constant up to 5 times the recommended dose for use in dogs. However, there is some evidence of enhanced drug accumulation and terminal elimination half-life prolongation when dogs are dosed for 45 days or longer. Peak drug concentrations can be expected to occur within about 7.5 hrs after oral administration. Corresponding peak concentration is approximately 0.464 mcg/mL following a 0.2 mg/kg oral dose. The drug is 97% bound to canine plasma proteins.

canine plasma proteins

Teffectiveness: The effectiveness of meloxicam was demonstrated in two field studies involving a total of 277 dogs representing various breeds, between six months and sixteen years of age, all diagnosed with osteoarthritis. Both of the placebo-controlled, masked studies were conducted for 14 days. All dogs received 0.2 mg/kg meloxicam on day 1. All dogs were maintained on 0.1 mg/kg oral meloxicam from days 2 through 14 of both studies. Parameters ady 1. And dogs were maintained on 0.1 mg/kg oral metoxicam rom days 2 inrough 14 or both soudes rearrange evaluated by veterinarians included lameness, weight-bearing, pain on palpation, and overall improvement. Parameters assessed by owners included mobility, ability to rise, limping, and overall improvement. The first field study (n=109), dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all parameters. In the second field study (n=48), dogs receiving meloxicam showed a clinical improvement after 14 days of therapy for all parameters; however, statistical significance was demonstrated only for the overall investigator evaluation on day 7, and for the owner evaluation on day 14.

Palatability: Metacam Oral Suspension was accepted by 100% of the dogs when veterinarians administered the initial dose into the mouth. Metacam Oral Suspension was accepted by 90% of the dogs (123/136) when administered by owners. Problems associated with administration included reliusal of food, resistance to swallowing and salivation.

Safety: Six Week Study

Satery: Six Week Study In a six week Study In a six week target animal safety study, meloxicam was administered orally at 1, 3, and 5X the recommended dose with no significant clinical adverse reactions. Animals in all dose groups (control, 1, 3 and 5X the recommended dose) exhibited some gastrointestinal distress (diarrhea and vormiting). No treatment-related changes were observed in hematological, blood chemistry, urinalysis, clotiting time, or buccal mucosal bleeding times. Necropsy results included stomach mucosal petechiae in one control dog, two dogs at the 3X and one dog at the 5X dose. Other macroscopic changes included areas of congestion or depression of the mucosa of the jelunum or ileum in three dogs at the 1X dose and in two dogs at the 5X dose. Similar changes were also seen in two dogs in the control group. There were no macroscopic small intestinal lesions observed in dogs receiving the 3X dose. Renai enlargement was reported during the necropsy of two dogs receiving the 3X dose and two dogs. Althere dogs at the 5X dose. Microscopic cammination of the stomach showed inflammatory mucosal lesions, epithelial regenerative hyperplasia or atrophy, and submucosal gland inflammation in two dogs at the recommended dose, epithelial regenerative the 3X and for udogs at the 5X dose. Similar observed inflammatory mucosal lesions, epithelial regenerative hyperplasia or atrophy, and submucosal gland inflammation in two dogs at the recommended dose. Here dogs at the 3X and for udogs at the 5X dose. Microscopic changes included minimal focal mucosal erosion affecting the villi, and were sometimes associated with mucosal congestion. These lesions were observed in the ileum of one control dog and in the jejunum of one dog at the recommended dose and two dogs at the 5X dose. <u>SiX Month Study</u>

of one control dog and in the jejunum of one dog at the recommended dose and two dogs at the 5X dose. <u>5X Month Study</u> In a six month target animal safety study, meloxicam was administered orally at 1, 3, and 5X the recommended dose with no significant clinical adverse reactions. All animals in all dose groups (controls, 1, 3, and 5X the recommended dose) exhibited some gastrointestinal distress (diarrhea and voniting). Treatment related changes seen in hematology and chemistry included decreased red blood cell counts in seven of 24 dogs (four 3X and three 5X dogs, decreased hematocrit in 18 of 24 dogs (including three control dogs), dose-related neutrophilia in one 1X, two 3X and three 5X dogs, evidence of regenerative anemia in two 3X and one 5X dog. Also noted were increased BUN in two 5X dogs and decreased albumin in one 5X dog.

Endoscopic changes consisted of reddening of the gastric mucosal surface covering less than 25% of the surface area. This was seen in three dogs at the recommended dose, three dogs at the 3X dose and two dogs at the 5X dose. Two control dogs exhibited reddening in conjunction with ulceration of the mucosa covering less than 25% of the surface area.

Gross gastrointestinal necropsy results observed included mild discoloration of the stomach or duodenum in one

Gross gastrointestinal necropsy results observed included mild discoloration of the stomach or duodenum in one dog at the 3X and in one dog at the 5X dose. Multificial pinpoint red foci were observed in the gastric fundic mucosa in one dog at the recommended dose, and in one dog at the 5X dose. No macroscopic or microscopic renal changes were observed in the duodenum of one dog at the six month study. Microscopic gastrointestinal findings were limited to one dog at the recommended dose, and two dogs at the 3X dose. Mild inflammatory mucosal inflittate was observed in the duodenum of one dog at the recommended dose. Mild congestion of the fundic mucosa and mild myositis of the outer mural musculature of the stomach were observed in the dose screeining the 3X dose. observed in two dogs receiving the 3X dose.

How Supplied:

Metacam Oral Suspension 1.5 mg/mL: 10, 32, 100 and 180 mL dropper bottles with measuring syringe. Metacam Oral Suspension 0.5 mg/mL: 15 mL and 30 mL dropper bottles with measuring syringe Storage: Store at controlled room temperature 59-86°F (15 - 30°C).

Manufactured for: Boehringer Ingelheim Vetmedica, Inc. St. Joseph, MO 64506 U.S.A. US Patent 6,184,220

Metacam is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, licensed to Boehringer Ingelheim Vetmedica Inc

6015161L-06-1007/601401-04 Code 601511, 601521, 601531, 601571/601411, 601421 Revised 08/2012

601501-01 08/2012

Boehringer Ingelheim